The need for a subsequent transvenous system in patients implanted with subcutaneous implantable cardioverter-defibrillator.

Humans Male Adult Middle Aged Aged Female Defibrillators, Implantable / adverse effects Death, Sudden, Cardiac / prevention & control Stroke Volume Retrospective Studies Treatment Outcome Ventricular Function, Left Renal Insufficiency, Chronic Adenosine Triphosphate
Need for antitachycardia pacing Subcutaneous implantable cardioverter-defibrillator Subcutaneous implantable cardioverter-defibrillator complications Sudden cardiac death Transvenous implantable cardioverter-defibrillator upgrade

Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
12 2022
Historique:
received: 06 05 2022
revised: 21 06 2022
accepted: 24 06 2022
pubmed: 6 7 2022
medline: 6 12 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

The absence of pacing capabilities may reduce the appeal of subcutaneous implantable cardioverter-defibrillator (S-ICD) devices for patients at risk for conduction disorders or with antitachycardia pacing (ATP)/cardiac resynchronization (CRT) requirements. Reports of rates of S-ICD to transvenous implantable cardioverter-defibrillator (TV-ICD) system switch in real-world scenarios are limited. The purpose of this study was to investigate the need for a subsequent transvenous (TV) device in patients implanted with an S-ICD and its predictors. All patients implanted with an S-ICD were enrolled from the multicenter, real-world iSUSI (International SUbcutaneouS Implantable cardioverter defibrillator) Registry. The need for a TV device and its clinical reason, and appropriate and inappropriate device therapies were assessed. Logistic regression with Firth penalization was used to assess the association between baseline and procedural characteristics and the overall need for a subsequent TV device. A total of 1509 patients were enrolled (age 50.8 ± 15.8 years; 76.9% male; 32.0% ischemic; left ventricular ejection fraction 38% [30%-60%]). Over 26.5 [13.4-42.9] months, 155 (10.3%) and 144 (9.3%) patients experienced appropriate and inappropriate device therapies, respectively. Forty-one patients (2.7%) required a TV device (13 bradycardia; 10 need for CRT; 10 inappropriate shocks). Body mass index (BMI) >30 kg/m A low rate (2.7%) of conversion from S-ICD to a TV device was observed at follow-up, with need for antibradycardia pacing, ATP, or CRT being the main reasons. BMI >30 kg/m

Sections du résumé

BACKGROUND
The absence of pacing capabilities may reduce the appeal of subcutaneous implantable cardioverter-defibrillator (S-ICD) devices for patients at risk for conduction disorders or with antitachycardia pacing (ATP)/cardiac resynchronization (CRT) requirements. Reports of rates of S-ICD to transvenous implantable cardioverter-defibrillator (TV-ICD) system switch in real-world scenarios are limited.
OBJECTIVE
The purpose of this study was to investigate the need for a subsequent transvenous (TV) device in patients implanted with an S-ICD and its predictors.
METHODS
All patients implanted with an S-ICD were enrolled from the multicenter, real-world iSUSI (International SUbcutaneouS Implantable cardioverter defibrillator) Registry. The need for a TV device and its clinical reason, and appropriate and inappropriate device therapies were assessed. Logistic regression with Firth penalization was used to assess the association between baseline and procedural characteristics and the overall need for a subsequent TV device.
RESULTS
A total of 1509 patients were enrolled (age 50.8 ± 15.8 years; 76.9% male; 32.0% ischemic; left ventricular ejection fraction 38% [30%-60%]). Over 26.5 [13.4-42.9] months, 155 (10.3%) and 144 (9.3%) patients experienced appropriate and inappropriate device therapies, respectively. Forty-one patients (2.7%) required a TV device (13 bradycardia; 10 need for CRT; 10 inappropriate shocks). Body mass index (BMI) >30 kg/m
CONCLUSION
A low rate (2.7%) of conversion from S-ICD to a TV device was observed at follow-up, with need for antibradycardia pacing, ATP, or CRT being the main reasons. BMI >30 kg/m

Identifiants

DOI: 10.1016/j.hrthm.2022.06.030 PMID: 35781042
pubmed: 35781042
pii: S1547-5271(22)02159-2
doi: 10.1016/j.hrthm.2022.06.030
pii:
doi:

Substances chimiques

Adenosine Triphosphate 8L70Q75FXE

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1958-1964

Informations de copyright

Copyright © 2022 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Alessio Gasperetti (A)

Cardiology Unit, Luigi Sacco University Hospital, Milan, Italy; Università degli Studi di Milano, Milan, Italy; Johns Hopkins University, Baltimore, Maryland; Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy. Electronic address: alessio.gasperetti93@gmail.com.

Marco Schiavone (M)

Università degli Studi di Milano, Milan, Italy.

Julia Vogler (J)

Department of Rhythmology, Herzzentrum Lubeck, Lubeck, Germany.

Mikael Laredo (M)

APHP, Hôpital Pitié Salpêtrière, Paris, France.

Fabian Fastenrath (F)

Cardiology Unit, University Medical Centre Mannheim, Manheim, Germany.

Pietro Palmisano (P)

Cardiology Unit, "Card. G. Panico" Hospital, Tricase, Italy.

Matteo Ziacchi (M)

Cardiology Unit, IRCCS, Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola Hospital, University of Bologna, Bologna, Italy.

Andrea Angeletti (A)

Cardiology Unit, IRCCS, Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola Hospital, University of Bologna, Bologna, Italy.

Gianfranco Mitacchione (G)

Cardiology Unit, Luigi Sacco University Hospital, Milan, Italy; Cardiology Unit, Spedali Civili Brescia, Brescia, Italy.

Lukas Kaiser (L)

St. George Klinik Asklepios, Hamburg, Germany.

Paolo Compagnucci (P)

Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy; Cardiology and Arrhythmology Clinic, University Hospital Ospedali Riuniti, Ancona, Italy.

Alexander Breitenstein (A)

University Hospital Zurich, Zurich, Switzerland.

Roberto Arosio (R)

Università degli Studi di Milano, Milan, Italy.

Francesco Vitali (F)

Cardiological Center, S. Anna University Hospital, Ferrara, Italy.

Silvana De Bonis (S)

Department of Cardiology, Castrovillari Hospital, Cosenza, Italy.

Francesco Picarelli (F)

Department of Cardiology, Campus Biomedico, Rome, Italy.

Michela Casella (M)

Cardiology and Arrhythmology Clinic, University Hospital Ospedali Riuniti, Ancona, Italy.

Luca Santini (L)

Cardiology Unit, Ospedale G.B. Grassi, Ostia, Italy.

Carlo Pignalberi (C)

Cardiology Unit, Ospedale San Filippo Neri, Rome, Italy.

Carlo Lavalle (C)

Cardiology Unit, Policlinico Umberto I, Rome, Italy.

Ennio Pisanò (E)

Cardiac Electrophysiology Unit, Vito Fazzi Hospital, Lecce, Italy.

Danilo Ricciardi (D)

Department of Cardiology, Campus Biomedico, Rome, Italy.

Leonardo Calò (L)

Cardiology Unit, Policlinico Casilino, Rome, Italy.

Antonio Curnis (A)

Cardiology Unit, Spedali Civili Brescia, Brescia, Italy.

Matteo Bertini (M)

Cardiological Center, S. Anna University Hospital, Ferrara, Italy.

Simone Gulletta (S)

Arrhythmology and Electrophysiology Unit, San Raffaele Hospital, IRCCS, Milan, Italy.

Antonio Dello Russo (A)

Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy; Cardiology and Arrhythmology Clinic, University Hospital Ospedali Riuniti, Ancona, Italy.

Nicolas Badenco (N)

APHP, Hôpital Pitié Salpêtrière, Paris, France.

Claudio Tondo (C)

Heart Rhythm Center, Monzino Cardiology Center, IRCCS, Milan, Italy.

Jürgen Kuschyk (J)

Cardiology Unit, University Medical Centre Mannheim, Manheim, Germany.

Roland Tilz (R)

Department of Rhythmology, Herzzentrum Lubeck, Lubeck, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany.

Giovanni B Forleo (GB)

Cardiology Unit, Luigi Sacco University Hospital, Milan, Italy.

Mauro Biffi (M)

Cardiology Unit, IRCCS, Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola Hospital, University of Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The need for a subsequent transvenous system...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › The need for a subsequent transvenous system...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › The need for a subsequent transvenous system...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › The need for a subsequent transvenous system...
questionsmedicales.fr › Équipement et fournitures › Prothèses et implants › Électrodes implantées › Défibrillateurs implantables › The need for a subsequent transvenous system...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Mort › Mort subite › Mort subite cardiaque › The need for a subsequent transvenous system...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Hémodynamique › Débit cardiaque › Débit systolique › The need for a subsequent transvenous system...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › The need for a subsequent transvenous system...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › The need for a subsequent transvenous system...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Fonction ventriculaire › Fonction ventriculaire gauche › The need for a subsequent transvenous system...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Insuffisance rénale chronique › The need for a subsequent transvenous system...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Ribonucléotides › Nucléotides adényliques › Adénosine triphosphate › The need for a subsequent transvenous system...